Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports outline breast cancer study results from S. Koscielny et al
March 27th, 2008
According to a study from Villejuif, France, "Purpose of review We critically review the methods used in microarray profiling, the reliability of published genomic signatures and the design of ongoing trials based on two of these signatures. Recent findings The main limitations of microarray prognostic signatures are known: instability of gene lists, overoptimistic performance indicators and inadequate validation." "Two commercially available gene expression-based prognostic tests (MammaPrint and OncotypeDX) are currently being assessed in two large randomized clinical trials. The overall concordance between patient classification resulting from these tests is only...
Source: Women's Health Weekly (2008-03-27)
|
